Mental health · Dallas area, TX
Mental health studies in Dallas area, TX
65 recruiting studies have a site in the Dallas area. This page includes nearby cities such as Fort Worth, Plano, Irving, Arlington.
65 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Janssen Research & Development, LLC
- Location
- Austin, TX + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Richardson, TX + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc.
- Location
- Houston, TX + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Coppell, TX + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Austin, TX + 24 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Bellaire, TX + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Dallas, TX + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Austin, TX + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- DeSoto, TX + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals, Inc.
- Location
- Austin, TX + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Houston, TX + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Reunion Neuroscience Inc
- Location
- Austin, TX + 26 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
TG Therapeutics, Inc.
- Location
- Richardson, TX + 1 other US site
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Austin, TX + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.
- Location
- Dallas, TX + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Brexanolone Lifting Outcomes Of Moms
Lipocine Inc.
- Location
- Plano, TX + 15 other US sites
- Eligibility basics
- Ages 15–45 · Women only
- RecruitingPhase 2
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
AbbVie
- Location
- Austin, TX + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb
- Location
- Austin, TX + 39 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc.
- Location
- DeSoto, TX + 22 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Austin, TX + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- DeSoto, TX + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Austin, TX + 20 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Minerva Neurosciences
- Location
- Richardson, TX + 12 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie
- Location
- Beaumont, TX + 30 other US sites
- Eligibility basics
- Ages 10–17
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.